TransMedics Group (NASDAQ:TMDX) Stock Price Down 2.6% – Should You Sell?

TransMedics Group, Inc. (NASDAQ:TMDX) traded down 2.6% on Tuesday . The stock traded as low as $84.00 and last traded at $84.57. 112,587 shares were traded during mid-day trading, a decline of 92% from the average session volume of 1,330,884 shares. The stock had previously closed at $86.84.

Analyst Upgrades and Downgrades

A number of research firms recently commented on TMDX. JPMorgan Chase & Co. reiterated a “neutral” rating and issued a $75.00 target price (down from $116.00) on shares of TransMedics Group in a research note on Tuesday, December 17th. Canaccord Genuity Group reiterated a “buy” rating and set a $104.00 price objective on shares of TransMedics Group in a research note on Tuesday, March 11th. Finally, Needham & Company LLC reissued a “hold” rating on shares of TransMedics Group in a research report on Wednesday, March 26th. Three investment analysts have rated the stock with a hold rating, seven have issued a buy rating and one has given a strong buy rating to the company. According to MarketBeat, the stock presently has an average rating of “Moderate Buy” and an average price target of $122.70.

TransMedics Group Stock Performance

The firm has a fifty day moving average of $71.19 and a 200 day moving average of $80.67. The company has a debt-to-equity ratio of 2.42, a current ratio of 8.20 and a quick ratio of 7.33. The stock has a market capitalization of $2.87 billion, a price-to-earnings ratio of 90.82 and a beta of 2.14.

Hedge Funds Weigh In On TransMedics Group

Several large investors have recently made changes to their positions in TMDX. Vanguard Group Inc. increased its holdings in TransMedics Group by 1.1% in the fourth quarter. Vanguard Group Inc. now owns 3,635,919 shares of the company’s stock valued at $226,700,000 after buying an additional 40,860 shares in the last quarter. FIL Ltd increased its stake in shares of TransMedics Group by 28.0% in the 4th quarter. FIL Ltd now owns 1,000,358 shares of the company’s stock valued at $62,372,000 after purchasing an additional 218,961 shares in the last quarter. Braidwell LP acquired a new position in TransMedics Group in the 4th quarter worth about $57,493,000. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC boosted its position in TransMedics Group by 16.6% during the fourth quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 903,086 shares of the company’s stock worth $56,307,000 after purchasing an additional 128,474 shares in the last quarter. Finally, Mackenzie Financial Corp grew its holdings in TransMedics Group by 73.0% in the fourth quarter. Mackenzie Financial Corp now owns 828,147 shares of the company’s stock valued at $51,635,000 after purchasing an additional 349,403 shares during the period. 99.67% of the stock is currently owned by institutional investors and hedge funds.

TransMedics Group Company Profile

TransMedics Group, Inc, a commercial-stage medical technology company, engages in transforming organ transplant therapy for end-stage organ failure patients in the United States and internationally. The company offers Organ Care System (OCS), a portable organ perfusion, optimization, and monitoring system that utilizes its proprietary and customized technology to replicate near-physiologic conditions for donor organs outside of the human body.